Agios Pharmaceuticals Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Agios Pharmaceuticals Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Cambridge
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
AGIO
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001439222

Board of directors

Follow this board

Chief executives

Brian Goff · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

12 of this board's directors also sit on 25 other boards.

Network of Agios Pharmaceuticals Inc.'s board connections Prime Medicine Inc. Prime Medicine Inc. ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals... Akebia Therapeutics Inc. Akebia Therapeutics In... Beam Therapeutics Inc. Beam Therapeutics Inc. BioMarin Pharmaceutical Inc. BioMarin Pharmaceutica... Denali Therapeutics Inc. Denali Therapeutics In... Disc Medicine Inc. Disc Medicine Inc. Editas Medicine Inc. Editas Medicine Inc. Enliven Therapeutics Inc. Enliven Therapeutics I... Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Incyte Corp. Incyte Corp. Intellia Therapeutics Inc. Intellia Therapeutics... Kymera Therapeutics Inc. Kymera Therapeutics In... Kyntra Bio Inc. Kyntra Bio Inc. Madrigal Pharmaceuticals Inc. Madrigal Pharmaceutica... Neogen Corporation Neogen Corporation Brian Goff Brian Goff Catherine Owen Adams Catherine Owen Adams Cynthia Smith Cynthia Smith David P. Schenkein David P. Schenkein David Scadden David Scadden Jacqualyn A. Fouse Jacqualyn A. Fouse Jay T. Backstrom Jay T. Backstrom Jeffrey D. Capello Jeffrey D. Capello John Maraganore John Maraganore Kaye I. Foster-Cheek Kaye I. Foster-Cheek Agios Pharmaceuticals Inc.
Shared director Other board Same sector +9 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$4,774,955
43 sales by 8 insiders
Date Insider Transaction Shares Price Value
Aug 4, 2026 Sarah Gheuens Officer (Chief Medical Officer) Open-market sale −30,000 $30.48 $914,400
Jul 8, 2026 Jay T. Backstrom Director Grant or award +1,447 — —
Jul 1, 2026 Sarah Gheuens Officer (Chief Medical Officer) Option exercise +8,375 — —
Jul 1, 2026 Sarah Gheuens Officer (Chief Medical Officer) Open-market sale −4,007 $37.56 $150,503
Jun 18, 2026 Rahul D. Ballal Director Option exercise +2,816 — —
Jun 18, 2026 Jeffrey D. Capello Director Option exercise +2,816 — —
Jun 18, 2026 Kaye I. Foster-Cheek Director Option exercise +2,816 — —
Jun 18, 2026 Jacqualyn A. Fouse Director Option exercise +2,816 — —
Jun 18, 2026 Maykin Ho Director Option exercise +2,816 — —
Jun 18, 2026 Catherine Owen Adams Director Option exercise +2,816 — —
Jun 18, 2026 David Scadden Director Option exercise +2,816 — —
Jun 18, 2026 Cynthia Smith Director Option exercise +2,816 — —
Jun 13, 2026 Catherine Owen Adams Director Option exercise +1,976 — —
Jun 13, 2026 Jeffrey D. Capello Director Option exercise +1,976 — —
Apr 2, 2026 Burns James William Officer (Chief Legal Officer) Option exercise +8,500 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.